Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2021

View Archived Issues

Identification of a vitamin D3 analogue inducing SREBP degradation without calcemic action

Results of phase I dose-escalation study of MVC-COV-1901 SARSCoV-2 vaccine candidate

ALICE study data support iadademstat with azacitidine in acute myeloid leukemia

Washington University reports dosimetry data for brain PET radiotracer [11C]CS1P1

Arrowhead voluntarily pauses phase I/II study of ARO-ENaC in CF

Sanofi initiates early clinical studies of SAR-444245

Genzyme patents new CFTR modulators

Omeros divulges new MASP2 inhibitors

Chinese researchers identify new CDK9 inhibitors

Sichuan Haisco Pharmaceutical identifies new ENPP2 inhibitors

Intestinal MYC modulates weight-related metabolic dysfunction

Beijing Tuojie Biopharmaceutical patents CaSR agonists

Initiation of phase II trial of Hepalatide in chronic hepatitis B

Amgen starts phase I study of AMG-609 in NAFLD

Pluripotent stem cell-derived CECs for the treatment of corneal dystrophies

Patient enrollment begins in phase II study of ADR-001 in severe pneumonia due to COVID-19

Sperogenix to develop Abbisko's ABSK-021 for rare neurological diseases in China

GNT-0003 restores UGT1A1 expression in patients with Crigler-Najjar syndrome

Phase Ib data presented for ulixertinib plus palbociclib in advanced solid tumors

SHR-1314 studied in phase II/III trial for active ankylosing spondylitis

Initiation of phase II study of HA-121-28 in advanced biliary tract cancer

Transcenta reports antitumor responses with TST-001 in gastric cancer

DPP3 is a marker of severity in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...